Results on disease control in first-line treatment in the pMMR group, the dMMR group caused by hypermethylation of the MLH1 promoter and the total group of patients with a dMMR tumour, were 83, 58 and 56%, respectively (Table 3). Here, MLH1 is linked to neoplasm.